# Phase II Study of TKI258 in Advanced Urothelial Carcinoma

> **NCT00790426** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 44 (actual)

## Conditions studied

- Urothelial Cancer

## Interventions

- **DRUG:** TKI258

## Key facts

- **NCT ID:** NCT00790426
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00790426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00790426, "Phase II Study of TKI258 in Advanced Urothelial Carcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00790426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*